Important Elements for the Diagnosis of Drug-Induced Liver Injury
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background & Aims Drug-induced liver disease is the leading cause of acute liver failure in the United States. Accurate reporting of drug-induced liver injury is essential for early detection of hepatotoxicity and for developing reliable, interpretable literature. We assessed the extent to which published case reports of drug-induced liver disease include sufficient clinical data for interpreting the cause of toxicity. Methods We developed a list of 42 pre-determined, specific minimal elements necessary in evaluating causality of drug-induced liver injury. We then analyzed 97 published case reports or series studies of hepatotoxicity from 6 drugs (from 3 classes): amoxicillin/clavulanic acid (n=35), troglitazone (n=32), rosiglitazone (n=10), pioglitazone (n=8), zafirlukast (n=8), and montelukast (n=4). Results Patient age, sex, primary disease, and drug name were reported in most, if not all, published case reports. However, many elements were under-reported; some publications did not mention initial bilirubin levels (12%), many did not provide initial alkaline phosphatase levels (58%), and others provided vague descriptions of how certain diagnoses were excluded, such as “tests for hepatitis A, B, and C were negative.” Data on abnormal results from serial liver tests were frequently absent. Exclusions of competing viral etiologies were reported in less than 50% of the studies. Conclusion Reports of drug-induced liver diseases often do not provide the data needed to determine the causes of the adverse effects. Efforts to promote and include a list of essential diagnostic elements in research articles could increase the quality and clinical utility of published case reports of drug toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., & Bonkovsky, H. L. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01707.x · Cited by 209
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
CASE REPORT: Troglitazone-Induced Fulminant Hepatic Failure
Murphy, E. J., Davern, T. J., Shakil, A. O., Shick, L., Masharani, U., Chow, H., Freise, C., Lee, W. M., & Bass, N. M. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005405526283 · Cited by 111
Cited by
Case definition and phenotype standardization in drug-induced liver injury
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., Hunt, C. M., Wilke, R. A., Avigan, M., Kaplowitz, N., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.58 · Cited by 944
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
RUCAM in Drug and Herb Induced Liver Injury: The Update
Danan, G., & Teschke, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010014 · Cited by 729
ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
Fontana, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.032 · Cited by 313
Drug induced liver injury: an update
Garcia-Cortes, M., Robles-Diaz, M., Stephens, C., Ortega-Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 286
Mechanisms of drug-induced liver injury: from bedside to bench
Tujios, S., & Fontana, R. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.22 · Cited by 277
Hepatotoxicity by drugs: The most common implicated agents
Björnsson, E. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020224 · Cited by 254
Review article: herbal and dietary supplement hepatotoxicity
Bunchorntavakul, C., & Reddy, K. R. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12109 · Cited by 249
Drug-induced autoimmune-like hepatitis
Czaja, A. J. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1611-4 · Cited by 235
Fontana, R. J., Hayashi, P. H., Gu, J., Reddy, K. R., Barnhart, H., Watkins, P. B., Serrano, J., Lee, W. M., Chalasani, N., Stolz, A., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.045 · Cited by 218
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts
Oketch-Rabah, H. A., Roe, A. L., Rider, C. V., Bonkovsky, H. L., Giancaspro, G. I., Navarro, V., Paine, M. F., Betz, J. M., Marles, R. J., Casper, S., et al. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.02.008 · Cited by 168
Reichenpfader, U., Gartlehner, G., Morgan, L. C., Greenblatt, A., Nussbaumer, B., Hansen, R. A., Van Noord, M., Lux, L., & Gaynes, B. N. (2014) · Drug Safety · doi:10.1007/s40264-013-0129-4 · Cited by 160
A revised electronic version of RUCAM for the diagnosis of DILI
Hayashi, P. H., Lucena, M. I., Fontana, R. J., Bjornsson, E. S., Aithal, G. P., Barnhart, H., Gonzalez‐Jimenez, A., Yang, Q., Gu, J., Andrade, R. J., et al. (2022) · Hepatology · doi:10.1002/hep.32327 · Cited by 160
“[14,15] We chose to only penalize ANA 1:80, ASMA 1:80, IgG 1.1 ULN.”
MethodInfluentialSelf-citationStine, J. G., & Lewis, J. H. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1127756 · Cited by 104
Drug-induced liver injury: Highlights of the recent literature
Real, M., Barnhill, M. S., Higley, C., Rosenberg, J., & Lewis, J. H. (2019) · Drug Safety · doi:10.1007/s40264-018-0743-2 · Cited by 103
Gupta, V., & Trivedi, P. (2018) · Lipid Nanocarriers for Drug Targeting · doi:10.1016/b978-0-12-813687-4.00015-3 · Cited by 96
Danan, G., & Teschke, R. (2018) · Drug Safety · doi:10.1007/s40264-018-0654-2 · Cited by 75
Teschke, R., Wolff, A., Frenzel, C., Schwarzenboeck, A., Schulze, J., & Eickhoff, A. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i1.17 · Cited by 70
Philips, C. A., Paramaguru, R., Joy, A. K., Antony, K. L., & Augustine, P. (2018) · Indian Journal of Gastroenterology · doi:10.1007/s12664-017-0815-8 · Cited by 66
Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States
Hayashi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020201 · Cited by 60
Benesic, A., Leitl, A., & Gerbes, A. L. (2016) · Gut · doi:10.1136/gutjnl-2015-309528 · Cited by 48
Hayashi, P. H., Barnhart, H. X., Fontana, R. J., Chalasani, N., Davern, T. J., Talwalkar, J. A., Reddy, K. R., Stolz, A. A., Hoofnagle, J. H., & Rockey, D. C. (2015) · Liver International · doi:10.1111/liv.12540 · Cited by 42
Self-citationHepatic Damage by Natural Remedies
Medina-Caliz, I., Gonzalez-Jimenez, A., Garcia-Cortes, M., Lucena, M. I., & Andrade, R. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1623518 · Cited by 40
Whritenour, J., Ko, M., Zong, Q., Wang, J., Tartaro, K., Schneider, P., Olson, E., Van Volkenburg, M., Serrano, J., Hayashi, P., et al. (2017) · Journal of Immunotoxicology · doi:10.1080/1547691x.2016.1254305 · Cited by 37
Abid, A., Subhani, F., Kayani, F., Awan, S., & Abid, S. (2020) · PLOS ONE · doi:10.1371/journal.pone.0231398 · Cited by 22
Scalfaro, E., Streefkerk, H. J., Merz, M., Meier, C., & Lewis, D. (2017) · Drug Safety · doi:10.1007/s40264-017-0541-2 · Cited by 16
Ayurvedic drug induced liver injury
Dalal, K. K., Holdbrook, T., & Peikin, S. R. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i31.1205 · Cited by 12
Causality assessment methods in drug-induced liver injury
Teschke, R., & Danan, G. (2018) · Methods in Pharmacology and Toxicology · doi:10.1007/978-1-4939-7677-5_27 · Cited by 10
(2013) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2013.d002x · Cited by 10
Metadata
- Authors
- Agarwal, V. K., McHutchison, J. G., & Hoofnagle, J. H.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 8
- Issue
- 5
- Pages
- 463-470
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2130302879
- Cited by
- 137
- References
- 6
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.